Background: Various reports have recently shown the efficacy of narrowband ultraviolet (UV) B phototherapy at 311 nm in the treatment of early stage mycosis fungoides (MF). Objectives: To examine the effectiveness and tolerability of monochromatic excimer light (MEL) at 308 nm as a first treatment for early stage MF (stage IA). Methods: Ten lesions from five patients with a clinical and histological diagnosis of MF were treated with repeated applications of MEL until complete remission was achieved or up to a maximum of 10 applications, with a cumulative dose of 308 nm UVB of between 6 and 12 J cm(-2). All patients were observed every 2 weeks for 2 months, with a 1-year follow-up. Results At present, all patients are in complete remission, with no side-effects. Conclusions: Based on these results, MEL can be considered a useful tool in the treatment of early stage MF
Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis-fungoides / Nistico', S; Costanzo, A; Saraceno, R; Chimenti, S. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - 151:5(2004), pp. 877-879. [10.1111/j.1365-2133.2004.06178.x]
Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis-fungoides
NISTICO' S;
2004
Abstract
Background: Various reports have recently shown the efficacy of narrowband ultraviolet (UV) B phototherapy at 311 nm in the treatment of early stage mycosis fungoides (MF). Objectives: To examine the effectiveness and tolerability of monochromatic excimer light (MEL) at 308 nm as a first treatment for early stage MF (stage IA). Methods: Ten lesions from five patients with a clinical and histological diagnosis of MF were treated with repeated applications of MEL until complete remission was achieved or up to a maximum of 10 applications, with a cumulative dose of 308 nm UVB of between 6 and 12 J cm(-2). All patients were observed every 2 weeks for 2 months, with a 1-year follow-up. Results At present, all patients are in complete remission, with no side-effects. Conclusions: Based on these results, MEL can be considered a useful tool in the treatment of early stage MFI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
